2026‑05‑17 – Chongqing Zhifei Biological Products Co Ltd: From Record‑Breaking Growth to a Stark Profit Decline
Chongqing Zhifei Biological Products Co Ltd (300122.SZ), once hailed as a “growth engine” in China’s vaccine sector, now faces a crisis that threatens its market dominance. The company’s 2025 annual report is a stark indictment of its business model, while the 2026 quarter‑end data reveal a precipitous slide in revenue and profitability that no investor can afford to ignore.
1. The 2025 Collapse: Record‑Low Revenue and Massive Losses
| Item | 2024 | 2025 (reported) | % Change |
|---|---|---|---|
| Revenue | 89.58 bn CNY | 89.58 bn CNY | -65.61 % |
| Net loss (parent‑owned) | 147.23 bn CNY | 147.23 bn CNY | -846.42 % |
| Operating cash flow | -42.24 bn CNY | +51.67 bn CNY | +222.33 % |
The 2025 results are the first ever negative earnings for Zhifei since its IPO in 2010. The company attributes the downturn to:
- Deep industry adjustments: Shrinking demand for core vaccines and intensified price competition.
- Inventory backlog: Excess stock of HPV vaccines and other immunisation products.
- Asset impairments: Significant write‑downs that eroded earnings.
Despite the bleak headline numbers, the firm has taken decisive steps to reverse the cash‑flow trend. It secured a 25 bn CNY research‑and‑development bond issuance and a 102 bn CNY syndicated loan, reducing debt leverage and injecting liquidity. Yet, the fundamental revenue engine is in crisis.
2. 2024 and 2023: A Tale of Two Segments
- 2023 – The company posted 52.96 bn CNY revenue but only 8.11 bn CNY net profit, a 7.54 % rise, while autonomous product revenue dropped 68.7 %. The majority of sales came from licensed products (51.9 bn CNY), reflecting a heavy dependence on third‑party brands such as Merck’s HPV vaccine and GSK’s shingles vaccine.
- 2024 H1 – Revenue fell 25.25 % to 18.27 bn CNY, and net profit slumped 47.27 %. Although market share remained robust, product promotion underperformed, and the company’s newly launched recombinant shingles vaccine was still in the nascent stages of market penetration.
These figures illustrate a dual‑track strategy: aggressive licensing to maintain cash flows, but a faltering proprietary pipeline that cannot sustain long‑term growth.
3. 2021 Break‑through – A Fading Legacy
In 2021, Zhifei recorded a sensational 306.52 bn CNY revenue (101.79 % YoY) and 102.09 bn CNY net profit (209.23 % YoY). This boom was largely driven by:
- COVID‑19 vaccine rollout: The CHO‑cell recombinant vaccine “Zhikewei” captured emergency‑use authorization and was a key driver of demand.
- Expanded tuberculosis products: New formulations of the bovine tuberculin vaccine broadened the company’s therapeutic reach.
- Robust R&D spending: 8.14 bn CNY invested in 29 research projects, 16 of which were in clinical phases.
That momentum evaporated within a few years, underscoring a lack of sustainable product diversification.
4. 2020 and 2022: High‑Growth Periods That Concealed Structural Weaknesses
- 2020 – Revenue of 151.90 bn CNY (+43.48 %) and net profit of 33.01 bn CNY (+39.51 %). The company benefitted from pandemic‑driven demand for non‑core vaccines, yet its profit margins remained modest (≈ 21 % net margin).
- 2022 – The company’s autonomous vaccine portfolio continued to struggle, with autonomous revenue falling 68.7 % in 2023, despite a 5.08 bn CNY R&D investment. This pattern suggests product development lagging behind market dynamics.
5. Current Cash‑Flow Position and Capital Structure
- Operating cash flow (2025): +51.67 bn CNY, a turnaround from negative cash flow in 2024.
- Total assets (2025): 317.20 bn CNY, a 38.16 % decline YoY.
- Equity (2025): 158.40 bn CNY, down 48.66 % YoY.
- Debt‑to‑equity: The company’s leveraged position has tightened thanks to new debt refinancing, but the equity base has shrunk dramatically, raising concerns about financial resilience.
6. Strategic Response: “Innovation‑driven” Shift or Mere Damage Control?
Zhifei’s management claims to be “pivoting from commercial to innovation”. They have:
- Paused HPV vaccine procurement with Merck, reducing inventory risk.
- Adjusted the strategic partnership with GSK to make procurement demand‑driven.
- Committed 14.36 bn CNY (16.03 % of revenue) to R&D in 2025, a significant increase.
However, the time lag between R&D investment and market entry is substantial in the biotech arena. The company’s recent pipeline (e.g., 23‑valent pneumococcal polysaccharide vaccine, 26‑valent conjugate vaccine) remains in early‑stage clinical trials, meaning returns may not materialize for several years. In the meantime, the licensed‑product revenue is eroding due to competitive pressures and shrinking demand.
7. Investor Takeaway
| Risk | Implication |
|---|---|
| Revenue concentration | 70 %+ of sales come from licensed products; any shift in licensing terms can be catastrophic. |
| Profitability erosion | Net loss of 147 bn CNY in 2025; profitability margin is a single digit. |
| R&D pipeline lag | Several high‑potential products still in Phase I‑III trials; returns delayed. |
| Equity dilution | Equity base has fallen 48 % YoY; potential for further dilution through new issuances. |
| Cash‑flow volatility | Operating cash flow turned positive, but total assets and liquidity remain under pressure. |
Given these dynamics, Zhifei’s valuation (≈ CNY 15 per share) appears undervalued only if the company can convincingly demonstrate a sustainable shift to proprietary product revenue. Until that transition materialises, the company’s stock risks further depreciation as markets price in the structural weaknesses.
